Danish fast-track model inspires growth in national reimbursement rates - Pharmaceutical Technology

As of 1 June 2026, a novel assessment process for PD-(L)1 drugs was implemented in Denmark by the Danish Medicines Council. The Danish Medicines Council decided to implement an amended assessment process for these frequently recommended PD-(L)1 inhibitors. Across the past four years, general reimbursement data in Denmark has remained consistent, with a noticeable increase in overall drug/indication reimbursement percentages from 53.6% in 2025 to the current level of 67.2% in 2026. Credit: Kittyfly / Shutterstock.com. Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare…

Source: Pharmaceutical Technology